Abstract:Objective: To evaluate the utility of a chromosomal microarray (CMA) in fetuses with isolated fetal growth restriction (FGR) and explore risk factors for the prediction of chromosomal aberration and perinatal adverse outcomes. Method: This study included 271 fetuses of estimated fetal weight less than the 3rd percentile without other structural malformation. Early-onset and late-onset FGR were defined as gestational weeks less than 32 weeks and more than 32 weeks respectively. These patients underwent quantitative fluorescent polymerase chain reaction (QF-PCR) and CMA as the first-line genetic detection strategy. Chromosomal anomalies were compared after stratified analysis by the early-onset and the late-onset FGR, including the absence or presence of ultrasound soft markers, abnormal amniotic fluid, abnormal umbilical Doppler, and gestational disorders. The follow-up time was within 1 year after birth. Logistic regression was used to seek risk predictors of chromosomal aberration and perinatal adverse outcomes for isolated FGR. Results: The CMA identified clinically significant variants in 18/271 (6.6%) fetuses, and variants of unknown significance (VOUS) in 15/271 (5.5%) fetuses. Stratified analysis showed that there was a higher incidence of clinically significant variants in fetuses with the early-onset FGR compared with late-onset FGR (8.7%, 17/195 vs. 1.3%, 1/76, p < 0.05). Regression analysis showed that early gestational age (GA) at diagnosis of FGR was the major risk factor for chromosomal aberration (OR = 0.846). By variable regression analysis, early GA at diagnosis and decreased estimated fetal weight (EFW) percentile of suspicion of FGR, asymmetrical FGR, abnormal amniotic fluid, and severe preeclampsia could all increase the risk of adverse outcomes of isolated FGR including intra-uterine fetal death (IUFD), termination of pregnancy (TOP), and preterm birth in pregnancies with FGR. Conclusion: This study emphasized the value of microarrays for unbalanced genomic variants in fetuses with isolated FGR, especially since the gestational age of nullipara was less than 32 weeks. Perinatal adverse outcomes of isolated FGR were influenced by multiple factors including GA and estimated fetal weight (EFW) percentile of suspicion of FGR, asymmetrical FGR, abnormal amniotic fluid, and severe preeclampsia.

Integrated Bioinformatics Analysis to Screen Hub Gene Signatures for Fetal Growth Restriction

Integrated Analysis of Key Genes and Pathways Involved in Fetal Growth Restriction and Their Associations With the Dysregulation of the Maternal Immune System

Whole-transcriptome Sequencing Uncovers Core Regulatory Modules and Gene Signatures of Human Fetal Growth Restriction

Integrated transcriptomic analysis and machine learning for characterizing diagnostic biomarkers and immune cell infiltration in fetal growth restriction

The Genetic and Clinical Outcomes in Fetuses With Isolated Fetal Growth Restriction: A Chinese Single-Center Retrospective Study

A Weighted Gene Co-Expression Network Analysis for Identifying Hub Genes in Preeclampsia-Induced Intrauterine Growth Restriction

Potential Association of Gut Microbial Metabolism and Circulating mRNA Based on Multiomics Sequencing Analysis in Fetal Growth Restriction

Galectin-1 Expression in the Serum and Placenta of Pregnant Women with Fetal Growth Restriction and Its Significance

The placental blood perfusion and LINC00473-mediated promotion of trophoblast apoptosis in fetal growth restriction

Progress in the understanding of the etiology and predictability of fetal growth restriction

Genome-Wide Analysis in the Study of the Fetal Growth Restriction Pathogenetics

Fetal genetic findings by chromosomal microarray analysis and karyotyping for fetal growth restriction without structural malformations at a territory referral center: 10-year experience

FGR-associated Placental Insufficiency and Capillary Angiogenesis Involves Disruptions in Human Placental Mirnas and Mrnas

Decreased PGF May Contribute to Trophoblast Dysfunction in Fetal Growth Restriction.

miR-1227-3p participates in the development of fetal growth restriction via regulating trophoblast cell proliferation and apoptosis

Genetics Etiologies Associated with Fetal Growth Restriction

Expression and significance of CEMIP and CYP11B2 in serum in women with foetal growth restriction

Fetal Growth Restriction and Methylation of Growth-Related Genes in the Placenta

Analysis of Gene Expression Profiles in the Liver of Rats With Intrauterine Growth Retardation

Dysfunction of Tregs Contributes to FGR Pathogenesis Via Regulating Smads Signalling Pathway.

Integrated Placental Modelling of Histology with Gene Expression to Identify Functional Impact on Fetal Growth